Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

Current Pharmaceutical Design

Volumn 19, Issue 13, 2013, Pages 2459-2473

  de Girolamo, Laura ^a   Lucarelli, Enrico ^b   Alessandri, Giulio ^c   Avanzini, Maria Antonietta ^d   Bernardo, Maria Ester ^e   Biagi, Ettore ^f   Brini, Anna Teresa ^g   D'Amico, Giovanna ^h   Fagioli, Franca ⁱ   Ferrero, Ivana ^j   Locatelli, Franco ^e,k   Maccario, Rita ^d   Marazzi, Mario ^l   Parolini, Ornella ^m   Pessina, Augusto ^g   Torre, Maria Luisa ^k  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF MILANO BICOCCA   (Italy)

ⁱ REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k UNIVERSITY OF PAVIA   (Italy)

^l OSPEDALE NIGUARDA CA GRANDA   (Italy)

^m Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

more..

Author keywords

Advanced therapy medicinal product; Cell therapy; Graft versus host disease; Immunomodulatory properties; Mesenchymal stem stromal cells; MSCs sources; Regenerative medicine; Transplantation

Indexed keywords

ALPHA4 INTEGRIN; CD11B ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD79A ANTIGEN; DOXORUBICIN; FIBRIN; GAMMA INTERFERON; GROWTH DIFFERENTIATION FACTOR 5; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OCTAMER TRANSCRIPTION FACTOR 4; PROSTAGLANDIN E2; STEROID; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ADAPTIVE IMMUNITY; ADIPOSE DERIVED STEM CELL; ARTICLE; BONE DEVELOPMENT; CANCER RISK; CANCER THERAPY; CD3+ T LYMPHOCYTE; CELL AGING; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CROHN DISEASE; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DISEASE SEVERITY; DNA DAMAGE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MITOSIS; NATURAL KILLER CELL; NONHUMAN; OSTEOGENESIS IMPERFECTA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLACENTA DERIVED STEM CELL; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; STROMA CELL; SYNOVIUM DERIVED MESENCHYMAL STEM CELL; THROMBOCYTE RICH PLASMA; TISSUE REGENERATION; WOUND HEALING;

HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; TISSUE THERAPY;

EID: 84877820900     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319130015     Document Type: Article

References (221)

1. Cohnheim J. Ueber entzundung und eiterung. Path Anat Physiol Klin Med. Berlin 1867; pp. 1-79.
2. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4: 267-74.
3. Zengin E, Chalajour F, Gehling UM, et al. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 2006; 133: 1543-51.
4. Cossu G, Bianco P. Mesoangioblasts-vascular progenitors for extravascular mesodermal tissues. Curr Opin Genet Dev 2003; 13: 537-42.
5. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
6. Caplan AI. What's in a Name? Tissue Eng 2010; 16: 2415-7.
7. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000; 113: 1161-6.
8. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
9. Prockop DJ. Marrow stromal cells as steam cells for nonhematopoietic tissues. Science 1997; 276: 71-4.
10. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A 2000; 97: 13625-30.
11. Quirici N, Scavullo C, de Girolamo L, et al. Anti-L-NGFR and-CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. Stem Cells Dev 2010; 19: 915-25.
12. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007; 109: 4245-8.
13. Buehring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci 2007; 1106: 262-71.
14. Jones EA, Kinsey SE, English A, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002; 46: 3349-60.
15. Gindraux F, Selmani Z, Obert L, et al. Human and rodent bone marrow mesenchymal stem cells that express primitive stem cell markers can be directly enriched by using the CD49a molecule. Cell Tissue Res 2007; 327: 471-83.
16. da Silva Meirelles L, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20: 419-27.
17. Salem HK, Thiemermann C. Mesenchymal Stromal Cells: Current Understanding and Clinical Status. Stem Cells 2010; 28: 585-96.
18. Izadpanah R, Trygg C, Patel B, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 2006; 99: 1285-97.
19. Mafi P, Hindocha S, Mafi R, Griffin M, Khan WS. Adult mesenchymal stem cells and cell surface characterization-a systematic review of the literature. Open Orthop J 2011; 5: 253-60.
20. Boheler KR. Functional markers and the 'homogeneity' of human mesenchymal stem cells. J Physiol 2004; 554: 592.
21. Blasi A, Martino C, Balducci L, et al. Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vasc Cell 2011; 3: 5.
22. Lorenz K, Sicker M, Schmelzer E, et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp Dermatol 2008; 17: 925-32.
23. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004; 110: 349-55.
24. De Siena R, Balducci L, Blasi A, et al. Omentum-derived stromal cells improve myocardial regeneration in pig post-infarcted heart through a potent paracrine mechanism. Exp Cell Res 2010; 316: 1804-15.
25. Cavallo C, Cuomo C, Fantini S, et al. Comparison of alternative mesenchymal stem cell sources for cell banking and musculoskeletal advanced therapies. J Cell Biochem 2011; 112: 1418-30.
26. Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-301.
27. Lee OK, Kuo TK, Chen W-M et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103: 1669-75.
28. Flynn A, Barry F, O'Brien T. UC blood-derived mesenchymal stromal cells: an overview. Cytotherapy 2007; 9: 717-26.
29. Bosch J, Houben AP, Radke TF, et al. Distinct differentiation potential of "MSC" derived from cord blood and umbilical cord: are cord-derived cells true mesenchymal stromal cells? Stem Cells Dev 2012; 21: 1977-88.
30. Kim Y, Kang H, Jang SW, et al. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem 2011; 28: 175-84.
31. Bieback K, Kern S, Kocaömer A, et al. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng 2008; 18: S71-6.
32. Pachón-Peña G, Yu G, Tucker A, et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol 2011; 226: 843-51.
33. Bochev I, Elmadjian G, Kyurkchiev D, et al. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol Int 2008; 32: 384-93.
34. Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 2009; 126: 37-42.
35. Noël D, Caton D, Roche S, et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials Exp Cell Res 2008; 314: 1575-84.
36. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-16.
37. Nilsson C, Aboud S, Karlen K, Hejdeman B, Urassa W, Biberfeld G. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vaccine Immunol 2008; 15: 585-9.
38. Goel RK, Suri V, Suri A, et al. Effect of bone marrow-derived mononuclear cells on nerve regeneration in the transection model of the rat sciatic nerve. J Clin Neurosci 2009; 16: 1211-7.
39. Muschler GF, Nitto H, Boehm CA, Easley KA. Age-and genderrelated changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001; 19: 117-25.
40. Ganong W. Review of medical physiology. McGraw-Hill: New York 2005.
41. Yeo C, Saunders N, Locca D, et al. Ficoll-Paque (TM) versus Lymphoprep (TM): a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen Med 2009; 4: 689-96.
42. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28: 766-72.
43. Chang Y, Hsieh P-H, Chao CCK. The efficiency of Percoll and Ficoll density gradient media in the isolation of marrow derived human mesenchymal stem cells with osteogenic potential. Chang Gung Med J 2009; 32: 264-75.
44. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001; 7: 211-28.
45. Faustini M, Bucco M, Chlapanidas T, et al. Nonexpanded mesenchymal stem cells for regenerative medicine: Yield in stromal vascular fraction from adipose tissues. Tissue Eng 2010; 16: 1515-21.
46. de Girolamo L, Sartori MF, Arrigoni E, et al. Human adiposederived stem cells as future tools in tissue regeneration: Osteogenic differentiation and cell-scaffold interaction. Int J Artif Organs 2008; 31: 467-79.
47. de Girolamo L, Lopa S, Arrigoni E, Sartori MF, Preis FWB, Brini AT. Human adipose-derived stem cells isolated from young and elderly women: their differentiation potential and scaffold interaction during in vitro osteoblastic differentiation. Cytotherapy 2009; 11: 793-803.
48. Schaeffler A, Buechler C. Concise review: Adipose tissue-derived stromal cells-Basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25: 818-27.
49. Kwon EB, Lee JY, Piao S, Kim IG, Ra JC. Comparison of human muscle-derived stem cells and human adipose-derived stem cells in neurogenic trans-differentiation. Korean J Urol 2011; 52: 852-7.
50. Kim SC, Han DJ, Lee JY. Adipose Tissue Derived Stem Cells for Regeneration and Differentiation into Insulin-Producing Cells. Curr Stem Cell Res Ther 2010; 5: 190-4.
51. Al Battah F, De Kock J, Vanhaecke T, Rogiers V. Current status of human adipose-derived stem cells: differentiation into hepatocytelike cells. ScientificWorldJournal 2011; 11: 1568-81.
52. Baer PC, Döring C, Hansmann M-L, Schubert R, Geiger H. New insights into epithelial differentiation of human adipose-derived stem cells. J Tissue Eng Regen Med 2011.
53. Choi YS, Dusting GJ, Stubbs S, et al. Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med 2010; 14: 878-89.
54. Bailo M, Soncini M, Vertua E, et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 2004; 78: 1439-48.
55. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22: 1338-45.
56. Soncini M, Vertua E, Gibelli L, et al. Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Reg Med 2007; 1: 296-305.
57. Parolini O, Alviano F, Bagnara GP, et al. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international workshop on placenta derived stem cells. Stem Cells 2008; 26: 300-11.
58. Portmann-Lanz CB, Schoebedein A, Huber A, et al. Placental mesenchymal stem cells as potential autologous graft for pre-and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664-73.
59. Castrechini NM, Murthi P, Gude NM, et al. Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. Placenta 2010; 31: 203-12.
60. Wulf GG, Viereck V, Hemmerlein B, et al. Mesengenic progenitor cells derived from human placenta. Tissue Eng 2004; 10: 1136-47.
61. Troyer DL, Weiss ML. Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26: 591-9.
62. Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton's Jelly stem cells: Future clinical applications. Placenta 2011; 32: 311-5.
63. Alaminos M, Perez-Koehler B, Garzon I, et al. Transdifferentiation potentiality of human Wharton's Jelly stem cells towards vascular endothelial cells. J Cell Physiol 2010; 223: 640-7.
64. Barlow S, Brooke G, Chatterjee K, et al. Comparison of human placenta-and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008; 17: 1095-107.
65. Brooke G, Tong H, Levesque J-P, Atkinson K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev 2008; 17: 929-40.
66. Mariotti E, Mirabelli P, Abate G, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow and placenta: CD10, CD49d, and CD56 make a difference. Stem Cells Dev 2008; 17: 1039-41.
67. Rossi D, Pianta S, Magatti M, Sedlmayr P, Parolini O. Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity. PLoS One 2012; 7: e46956.
68. Wolbank S, Peterbauer A, Fahrner M, et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng 2007; 13: 1173-83.
69. Magatti M, De Munari S, Vertua E, et al. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant 2009; 18: 899-914.
70. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928-42.
71. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues-Superiority of synovium as a cell source. Arthritis Rheum 2005; 52: 2521-9.
72. Theoret CL, Barber SM, Moyana T, Townsend HGG, Archer JF. Repair and function of synovium after arthroscopic synovectomy of the dorsal compartment of the equine antebrachiocarpal joint. Vet Surg 1996; 25: 142-53.
73. Jones EA, Crawford A, English A, et al. Synovial fluid mesenchymal stem cells in health and early osteoarthritis-Detection and functional evaluation at the single-cell level. Arthritis Rheum 2008; 58: 1731-40.
74. McGonagle D, Jones E. A potential role for synovial fluid mesenchymal stem cells in ligament regeneration. Rheumatology (Oxford) 2008; 47: 1114-6.
75. Wickham MQ, Erickson GR, Gimble JM, Vail TP, Guilak F. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop Relat Res 2003: 196-212.
76. Nakahara H, Goldberg VM, Caplan AI. Culture-expanded human periosteal-derived cells exhibit osteochondral potential in vivo. J Orthop Res 1991; 9: 465-76.
77. Brighton CT, Lorich DG, Kupcha R, Reilly TM, Jones AR, Woodbury RA. The pericyte as a possible osteoblast progenitorcell. Clin Orthop Relat Res 1992: 287-99.
78. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000; 2: 477-88.
79. Young HE, Steele TA, Bray RA, et al. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec 2001; 264: 51-62.
80. Osyczka AM, Noth U, Danielson KG, Tuan RS. Different osteochondral potential of clonal cell lines derived from adult human trabecular bone. Ann N Y Acad Sci 2002; 961: 73-7.
81. Lu HH, Kofron MD, El-Amin SF, Attawia MA, Laurencin CT. In vitro bone formation using muscle-derived cells: a new paradigm for bone tissue engineering using polymer-bone morphogenetic protein matrices. Biochem Biophys Res Commun 2003; 305: 882-9.
82. Hu Y, Liao LM, Wang LY, et al. Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med 2003; 141: 342-9.
83. Trubiani O, Di Primo R, Traini T, et al. Morphological and cytofluorimetric analysis of adult mesenchymal stem cells expanded ex vivo from periodontal ligament. Int J Immunopathol Pharmacol 2005; 18: 213-21.
84. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG. Multipotent menstrual blood stromal stem cells: isolation, characterization, and differentiation. Cell Transplant 2008; 17: 303-11.
85. Patki S, Kadam S, Chandra V, Bhonde R. Human breast milk is a rich source of multipotent mesenchymal stem cells. Hum Cell 2010; 23: 35-40.
86. Bharadwaj S, Liu G, Shi Y, et al. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng 2011; 17: 2123-32.
87. Bernardo ME, Avanzini MA, Ciccocioppo R, et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy 2009; 11: 825-36.
88. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86.
89. Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004; 9: 747-56.
90. Shahdadfar A, Fronsdal K, Haug T, Reinholt FP, Brinchmann JE. In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005; 23: 1357-66.
91. Jung S, Sen A, Rosenberg L, Behie LA. Identification of growth and attachment factors for the serum-free isolation and expansion of human mesenchymal stromal cells. Cytotherapy 2010; 12: 637-57.
92. Doucet C, Ernou I, Zhang YZ, et al. Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228-36.
93. Avanzini MA, Bernardo ME, Cometa AM, et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood-and bone marrow-derived progenitors. Haematologica 2009; 94: 1649-60.
94. Lucarelli E, Beccheroni A, Donati D, et al. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 2003; 24: 3095-100.
95. Bernardo ME, Avanzini MA, Perotti C, et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007; 211: 121-30.
96. Schallmoser K, Bartmann C, Rohde E, et al. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica 2010; 95: 867-74.
97. Dazzi F, Krampera M. Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol 2011; 24: 49-57.
98. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
99. Ren G, Zhang L, Zhaon X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
100. Nemeth K, Mayer B, Mezey E. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands. J Mol Med 2010; 88: 5-10.
101. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a proinflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5: e10088.
102. Wagner W, Ho AD, Zenke M. Different Facets of Aging in Human Mesenchymal Stem Cells. Tissue Eng 2010; 16: 445-53.
103. Mohseny AB, Szuhai K, Romeo S, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009; 219: 294-305.
104. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
105. Wang Y, Huso DL, Harrington J, et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7: 509-19.
106. Achille V, Mantelli M, Arrigo G, et al. Cell-cycle phases and genetic profile of bone marrow-derived mesenchymal stromal cells expanded in vitro from healthy donors. J Cell Biochem 2011; 112: 1817-21.
107. Rubio D, Garcia-Castro J, Martin MC, et al. Spontaneous human adult stem cell transformation (Retracted article. See vol. 70, pg. 6682, 2010). Cancer Res 2005; 65: 3035-9.
108. Rosland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation (This article contains errors due to a cross contamination of the cell lines we used. To correct this issue we published a letter in Cancer Res. 2010 Aug 1,70(15),6393-6). Cancer Res 2009; 69: 5331-9.
109. Garcia S, Bernad A, Martin MC, et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010; 316: 1648-50.
110. Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects crosscontamination: putting the research field on track (Correction letter for Cancer Res. 2009 Jul 1, 69(13), 5331-9). Cancer Res 2010; 70: 6393-6.
111. Lalu MM, McIntyre L, Pugliese C, et al. Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS One 2012; 7:e47559.
112. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrowderived mesenchymal stem cells do not undergo transformation after long-term In vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67: 9142-9.
113. Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006; 6: 435-41.
114. Rehman J, Traktuev D, Li JL, Merfeld-Clauss S, et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-8.
115. Sorrell JM, Baber MA, Caplan AI. Influence of adult mesenchymal stem cells on in vitro vascular formation. Tissue Eng 2009; 15: 1751-61.
116. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrowderived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176: 57-66.
117. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-6.
118. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-34.
119. Götherström C, Ringdén O, Tammik C, Zetterberg E, Westgren M, Le Blanc K. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol 2004; 190: 239-45.
120. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-20.
121. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-90.
122. Locatelli F, Maccario R, Frassoni F. Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immunemediated disorders? Haematologica 2007; 92: 872-7.
123. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-36.
124. Raffaghello L, Bianchi G, Bertolotto M, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells 2008; 26: 151-62.
125. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4(+), T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-25.
126. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-72.
127. Comoli P, Ginevri F, Maccario R, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-202.
128. Collino F, Deregibus MC, Bruno S, et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of mirnas. PloS One 2010; 5: e11803.
129. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5: 91-116.
130. Alt EU, Senst C, Murthy SN, et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res 2012; 8: 215-25.
131. Jakob F, Ebert R, Rudert M, et al. In situ guided tissue regeneration in musculoskeletal diseases and aging Implementing pathology into tailored tissue engineering strategies. Cell Tissue Res 2012; 347: 725-35.
132. Mansilla E, Diaz Aquino V, Zambon D, et al. Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes? Stem Cells Int 2011; 2011: 1-10.
133. Guan M, Yao W, Liu R, et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nature Med 2012; 18: 456-63.
134. Cai B, Zhu S, Li J, Chen N, Liu Y, Lu Y. Bone marrow-derived mesenchymal stem cells protected rat cardiomyocytes from premature senescence. Int J Cardiol 2012; 154: 180-223.
135. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006; 116: 1865-77.
136. Vassalli G, Moccetti T. Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Med Wkly 2011; 141: 1-6.
137. Lee S, Szilagyi E, Chen L, et al. Activated mesenchymal stem cells increase wound tensile strength in aged mouse model via macrophages. J Surg Res 2012.
138. Wong RSY. Mesenchymal Stem Cells: Angels or Demons? J Biomed Biotechnol 2011; 2011.
139. Ding DC, Shyu WC, Lin SZ. Mesenchymal Stem Cells. Cell Transplant 2011; 20: 5-14.
140. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007; 213: 341-7.
141. Otto WR, Wright NA. Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair 2011; 4: 20.
142. Kurtz A. Mesenchymal stem cell delivery routes and fate. Int J Stem Cells 2008; 1: 1-7.
143. ClinicalTrials. gov [homepage on the Internet]. The U.S. National Institutes of Health [cited 2012 Oct 18]. Available from: http://www.clinicaltrials.gov/
144. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010; 12: 87-117.
145. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932-37.
146. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo-expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-7.
147. Duijvenstein M, Vos ACW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-9.
148. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60: 788-98.
149. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309-13.
150. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110: 1362-9.
151. Kunter U, Rong S, Boor P, et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J Am Soc Nephrol 2007; 18: 1754-64.
152. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-41.
153. Ball LM, Bernardo ME, van Tol MJD, et al. Mesenchymal stromal cells are highly effective in steroid-refractory, grade III-IV acute graft-versus-host disease in children. Bone Marrow Transplant 2011; 46: 6-7.
154. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood and Marrow Transplant 2009; 15: 804-11.
155. Lucchini G, Dander E, Pavan F, et al. Platelet-lysate-expanded mesenchymal stromal cells for the treatment of steroid resistant GvHD: clinical results and biological readouts in a multicentre study. Bone Marrow Transplant 2012; 47: 55-6.
156. Introna M, Lucchini G, Dander E, et al. Safe and effective treatment of Graft versus Host Disease with platelet lysateexpanded human mesenchymal stromal cells: a phase 1 study on 47 adult and pediatric patients. Blood (ASH Annual Meeting Abstracts) 2012; 120: 743.
157. Choi SW, Levine JE, Ferrara JLM. Pathogenesis and management of Graft-versus-Host Disease. Immunol Allergy Clin North Am 2010; 30: 75-101.
158. Dander E, Lucchini G, Vinci P, et al. Mesenchymal stromal cells for the treatment of Graft-versus-Host Disease: understanding the in vivo biological effect through patient immune monitoring. Leukemia 2012; 26: 1681-4.
159. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-66.
160. Gonzalez MA, Gonzalez-Rey E, Rico L, Buescher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136: 978-89.
161. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009; 183: 7787-98.
162. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48: 1416-23.
163. Almeida-Porada G, Porada CD, Tran N, Zanjani ED. Cotransplantation of human stromal cell progenitors into preimmune fetal sheep results in early appearance of human donor cells in circulation and boosts cell levels in bone marrow at later time points after transplantation. Blood 2000; 95: 3620-7.
164. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-16.
165. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-98.
166. Bernardo ME, Ball LM, Cometa AM, et al. Co-infusion of ex vivoexpanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011; 46: 200-7.
167. Otsuru S, Gordon PL, Shimono K, et al. Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood 2012; 120: 1933-41.
168. Shekkeris AS, Jaiswal PK, Khan WS. Clinical applications of mesenchymal stem cells in the treatment of fracture non-union and bone defects. Curr Stem Cell Res Ther 2012; 7: 127-33.
169. Morishita T, Honoki K, Ohgushi H, Kotobuki N, Matsushima A, Takakura Y. Tissue engineering approach to the treatment of bone tumors: three cases of cultured bone grafts derived from patients' mesenchymal stem cells. Artif Organs 2006; 30: 115-8.
170. Ohgushi H, Kotobuki N, Funaoka H, et al. Tissue engineered ceramic artificial joint-ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. Biomaterials 2005; 26: 4654-61.
171. Connolly JF. Injectable bone-marrow preparations to stimulate osteogenic repair. Clin Orthop Relat Res 1995: 8-18.
172. Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop 2009; 43: 40-5.
173. Gangji V, De Maertelaer V, Hauzeur J-P. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone 2011; 49: 1005-9.
174. Di Bella C, Dozza B, Frisoni T, Cevolani L, Donati D. Injection of demineralized bone matrix with bone marrow concentrate improves healing in unicameral bone cyst. Clin Orthop Relat Res 2010; 468: 3047-55.
175. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011; 5: 146-50.
176. Haleem AM, El Singergy AA, Sabry D, et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage 2010; 1: 253-61.
177. Acharya C, Adesida A, Zajac P, et al. Enhanced chondrocyte proliferation and mesenchymal stromal cells chondrogenesis in coculture pellets mediate improved cartilage formation. J Cell Physiol 2012; 227: 88-97.
178. Cooke ME, Allon AA, Cheng T, et al. Structured threedimensional co-culture of mesenchymal stem cells with chondrocytes promotes chondrogenic differentiation without hypertrophy. Osteoarthritis Cartilage 2011; 19: 1210-8.
179. Gaetani P, Torre ML, Klinger M, et al. Adipose-derived stem cell therapy for intervertebral disc regeneration: An in vitro reconstructed tissue in alginate capsules. Tissue Eng 2008; 14: 1415-23.
180. Chlapanidas T, Farago S, Mingotto F, et al. Regenerated silk fibroin scaffold and infrapatellar adipose stromal vascular fraction as feeder-layer: a new product for cartilage advanced therapy. Tissue Eng 2011; 17: 1725-33.
181. Slynarski K, Deszczynski J, Karpinski J. Fresh bone marrow and periosteum transplantation for cartilage defects of the knee. Transplantat Proc 2006; 38: 318-9.
182. de Girolamo L, Bertolini G, Cervellin M, Sozzi G, Volpi P. Treatment of chondral defects of the knee with one step matrixassisted technique enhanced by autologous concentrated bone marrow: In vitro characterisation of mesenchymal stem cells from iliac crest and subchondral bone. Injury 2010; 41: 1172-7.
183. Buda R, Vannini F, Cavallo M, Grigolo B, Cenacchi A, Giannini S. Osteochondral lesions of the knee: a new one-step repair technique with bone-marrow-derived cells. J Bone Joint Surg Am 2010; 92A: 2-11.
184. Guo X, Zheng Q, Yang S, et al. Repair of full-thickness articular cartilage defects by cultured mesenchymal stem cells transfected with the transforming growth factor beta(1) gene. Biomed Mater 2006; 1: 206-15.
185. Cucchiarini M, Ekici M, Schetting S, Kohn D, Madry H. Metabolic activities and chondrogenic differentiation of human mesenchymal stem cells following recombinant adeno-associated virus-mediated gene transfer and overexpression of fibroblast growth factor 2. Tissue Eng 2011; 17: 1921-33.
186. Price R, Anthony E, Myers S, Navsaria H. Tissue engineering for skin transplantation. In: Van Blitterswijk C eds. Tissue Engineering. Elsevier Inc. 2008; pp. 507-32.
187. Marazzi M, Crovato F, Bucco M, et al. GMP-compliant culture of human hair follicle cells for encapsulation and transplantation. Cell Transplant 2012; 21: 373-8.
188. Arno A, Smith AH, Blit PH, Al Shehab M, Gauglitz GG, Jeschke MG. Stem cell therapy: A new treatment for burns? Pharmaceuticals 2011; 4: 1355-80.
189. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975; 6: 331-43.
190. Schreml S, Szeimies R-M, Prantl L, Landthaler M, Babilas P. Wound healing in the 21st century. J Am Acad Dermatol 2010; 63: 866-81.
191. Berthiaume F, Maguire TJ, Yarmush ML. Tissue engineering and regenerative medicine: history, progress, and challenges. Ann Rev Chem Biomol Eng 2011; 2: 403-30.
192. Lau K, Paus R, Tiede S, Day P, Bayat A. Exploring the role of stem cells in cutaneous wound healing. Exp Dermatol, 2009; 18: 921-33.
193. Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds. Stem Cell Res Ther 2010; 1: 30.
194. Nauta A, Gurtner GC, Longaker MT. Wound healing and regenerative strategies. Oral Diseases 2011; 17: 541-9.
195. Guisantes E, Fontdevila J, Rodríguez G. Autologous fat grafting for unaesthetic scars correction. Ann Plast Surg 2011.
196. Klinger M, Marazzi M, Vigo D, Torre M. Fat injection for cases of severe burn outcomes: A new perspective of scar remodeling and reduction. Aesthetic Plast Surg 2008; 32: 465-9.
197. Kaufman MR, Bradley JP, Dickinson B, et al. Autologous fat transfer national consensus survey: Trends in techniques for harvest, preparation, and application, and perception of short-and long-term results. Plast Reconstr Surg 2007; 119: 323-31.
198. Tremolada C, Palmieri G, Ricordi C. Adipocyte transplantation and stem cells: plastic surgery meets regenerative medicine. Cell Transplant 2010; 19: 1217-23.
199. Mareschi K, Novara M, Rustichelli D, et al. Neural differentiation of human mesenchymal stem cells: evidence for expression of neural markers and eag K+ channel types. Exp Hematol 2006; 34: 1563-72.
200. Wislet-Gendebien S, Laudet E, Neirinckx V, Rogister B. Adult Bone Marrow: Which stem cells for cellular therapy protocols in neurodegenerative disorders? J Biomed Biotechnol 2012; 2012.
201. Zhang Z, Wang X, Wang S. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In vitro Cell Dev Biol Anim 2008; 44: 169-77.
202. Vercelli A, Mereuta OM, Garbossa D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2008; 31: 395-405.
203. Ferrero I, Mazzini L, Rustichelli D, et al. Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant 2008; 17: 255-66.
204. Mazzini L, Mareschi K, Ferrero I, et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy 2012; 14: 56-60.
205. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of trail can eliminate metastatic cancer. Cancer Res 2009; 69: 4134-42.
206. Nakamizo A, Marini F, Amano T, et al. Human bone marrowderived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-18.
207. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 2004; 11: 1155-64.
208. Menon LG, Shi VJ, Carroll RS. Mesenchymal stromal cells as a drug delivery system. In: Menon LG SV, Carroll RS Eds. StemBook: Cambridge MA, Harvard Stem Cell Institute 2008.
209. Stagg J, Lejeune L, Paquin A, Galipeau J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Human Gene Ther 2004; 15: 597-608.
210. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-13.
211. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603-8.
212. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012; 64: 739-48.
213. Zhang X-B, Beard BC, Trobridge GD, et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest 2008; 118: 1502-10.
214. Cocke KS, Updyke LW, Wierda D. Mouse bone marrow stromal cells can accumulate and release cytotoxic concentrations of doxorubicin into the hematopoietic microenvironment. In vitro Toxicol 1993; 6: 243-56.
215. Pessina A, Piccirillo M, Mineo E, et al. Role of SR-4987 stromal cells in the modulation of doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (CFU-GM). Life Sci 1999; 65: 513-23.
216. Pessina A, Bonomi A, Cocce V, et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PloS One 2011; 6: e28321.
217. Pessina A, Cocce V, Bonomi A, et al. Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with paclitaxel. Anticancer Agents Med Chem 2012.
218. European Parlament. Directive 2001/83/EC of the european parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use. 2001.
219. Sensebe L. Clinical grade production of mesenchymal stem cells. Biomed Mater Eng 2008; 18: 3-10.
220. Lowdell MW, Birchall M, Thrasher AJ. Use of compassionate-case ATMP in preclinical data for clinical trial applications. Lancet 2012; 379: 2341.
221. Belardelli F, Rizza P, Moretti F, Carella C, Galli MC, Migliaccio G. Translational research on advanced therapies. Ann Istit Sup San 2011; 47: 72-8.